Notícias Akero Therapeutics Inc - AKRO | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (AKRO) Notícias

Akero Therapeutics Inc (AKRO)

45,22

0,56

(1,25%)

Fechado 22 Março 5:00PM

Atrasado por 15 minutos

44,94

-0,28

(-0,62%)

Após o horário de negociação: 8:59PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Form 8-K - Current report

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Form 4 - Statement of changes in beneficial ownership of securities

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

1
2
3
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Akero Therapeutics

John B Sanfilippo and Son

Payton Planar Magnetics

Cambria Foreign Sharehol...

Enlight Renewable Energy

Defiance Daily Target 2X...

Fs Credit Opportunities

Lululemon Athletica

Regeneron Pharmaceuticals

Anheuser Busch InBev SA NV

Angel Oak Mortgage REIT

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições